Latest Conference Content

Slowing the loss of ambulation in patients with Duchenne muscular dystrophy (DMD) may also mitigate worsening disease burden and overall function, according to a pair of posters presented at ISPOR 2024.

A session at the SLEEP 2024 Annual Meeting discussed the various inequities in sleep that persist in individuals who are incarcerated, attend university, or work at hospitals.

Posters presented at ASCO 2024 found positive responses in the prediction of tumor types and prognostic outcomes in patients with advanced solid tumors and HR+/HER2-negative (HER2–) metastatic breast cancer.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, discusses promising pharmacological treatments for patients with idiopathic hypersomnia.

A symposium held at the SLEEP 2024 Annual Meeting discussed updates in narcolepsy and idiopathic hypersomnia treatment, specifically in guidelines for treatment and testing in this population.

Use of sodium oxybate and low-sodium oxybate led to meaningful improvements in patients with hypersomnia and narcolepsy regardless of comorbidities.

Chief Health Equity Officer and Senior Vice President Aletha Maybank, MD, MPH, of the American Medical Association (AMA), delivered a powerful plenary session at the CMS Health Equity conference exploring the changes sparked by pivotal moments within the last 5 years.

In the final overall survival analysis of the phase 3 CARES-310 trial, frontline camrelizumab plus rivoceranib continued to show clinically meaningful survival benefits vs sorafenib for hepatocellular carcinoma (HCC).

Hrayr Attarian, MD, professor of neurology, Northwestern Feinberg School of Medicine, shares findings on sleep inequities that have greatly impacted refugees.

Caitlin Kindberg, patient advocate in Nashville, Tennessee, discusses her lived experience as an individual with idiopathic hypersomnia, and how the sleep disorder impacts her day-to-day life.

The relationships among bipolar disorder, sleep, and circadian rhythms were emphasized in a panel held at SLEEP 2024.

This new analysis of nivolumab presented at ASCO 2024 shows the immune checkpoint inhibitor did not convery benefit when added to a regimen of neoadjuvant carboplatin, paclitaxel, and radiation.

The session held at SLEEP 2024 focused on the challenges of collecting data on sleep and circadian rhythms in adolescents, as well as the difference between home and lab measurements.

An in-depth analysis of minimal residual disease (MRD) negativity results from the PERSEUS trial shows patients whose treatment regimen included subcutaneous daratumumab had responses that deepened over time.

Christopher Depner, PhD, professor of health and kinesiology, University of Utah, shares the challenges of measuring sleep with wearable devices due to nonadherence and the need for metrics like the Sleep Regularity Index.

Results for the first 10 patients offer promising signs for giving patients with multiple myeloma a prophylactic dose of tocilizumab before they are treated with the bispecifc antibody teclistamab.

The findings can help reduce barriers that delay the onset of recommended palliative care in advanced cancer.

The idea that patients could get better responses with shorter courses of therapy runs counter to the current standard of care in melanoma.

Within the GAIN-S model, geriatric care assessments among older patients with cancer are combined with care interventions, and it is delivered soon before patients have an intervention on their cancer therapy, says William Dale, MD, PhD, FASCO, City of Hope.

A pair of late-breaking trials, LAURA and ADRIATIC, promise practice-changing news in lung cancer.

The BE-a-PAL study investigated potential of an algorithm-based default palliative care referral among patients who have stage III or IV lung or noncolorectal gastrointestinal cancer.

Attendees packed a session on multicancer early detection (MCED) on the first day of the 2024 American Society of Clinical Oncology annual meeting.

The annual session on newly approved drugs reviewed adverse effects, mechanisms of action, and real-world experiences.

Glofitamab is currently being investigated in a phase 1/2, multicenter, open-label, dose-escalation study as monotherapy and in combination with obinutuzumab, following 1-time fixed-dose pretreatment with obinutuzumab for B-cell non-Hodgkin lymphoma, of which mantle cell lymphoma (MCL) is a rare type.

The TROPiCS-02 trial studied sacituzumab govitecan vs physician’s choice of chemotherapy for HR+/HER2– breast cancer.

Surya Bhatt, MD, MSPH, of the University of Alabama at Birmingham, discussed the challenges of diagnosing chronic obstructive pulmonary disease (COPD) with type 2 inflammation, as well as the promising efficacy of dupilumab in treating this condition.

Presenters from CMS and the CDC explored the importance of standardizing health equity data collection at the 2024 CMS Health Equity Conference.

The annual conference taking place from June 1 to June 5, 2024, will feature sessions on the relationship between mental health and sleep, artificial intelligence in sleep, and different sleep conditions.